Results 211 to 220 of about 2,046,127 (279)

Urinary Metabolic and Hemodynamic Protein Signatures in Canagliflozin Treated Patients With Diabetic Kidney Disease: Findings From CREDENCE

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) provide kidney protection in patients with diabetic kidney disease (DKD). There is limited knowledge about the mechanisms by which they protect the kidney. We investigated which urinary proteins and pathways are associated with progressive kidney disease and canagliflozin treatment.
Mark André de la Rambelje   +10 more
wiley   +1 more source

Can a Single Maximally Fortified Food Improve Glycaemia in Type 2 Diabetes? Randomised Crossover Trial of High‐Fibre High‐Protein Bread

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To examine the effects of a maximally fortified high‐fibre high‐protein bread on glycaemia in free‐living adults with Type 2 diabetes. Research Design and Methods Participants were provided commercially produced high‐fibre high‐protein bread (fibre 8.1 g and protein 19.5 g/100 g) fortified with lupin flour, pea protein and wheat ...
Md. Altaf Hossain   +4 more
wiley   +1 more source

Whole Exome Sequencing in Drug-Induced Angioedema Caused by Angiotensin-Converting Enzyme Inhibitors: A Pilot Study in Five Patients. [PDF]

open access: yesJ Clin Med
Mendoza-Alvarez A   +10 more
europepmc   +1 more source

Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Finerenone was approved in China in 2022 for adult patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D). This study aimed to characterize Chinese patients with CKD and T2D who initiated finerenone in routine clinical practice and to evaluate treatment outcomes.
Yan Kong   +7 more
wiley   +1 more source

Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT‐1 Randomized Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes.
Tomoaki Morioka   +14 more
wiley   +1 more source

A comparative analysis of cell death signalling in RNA and DNA virus infections and potential inhibitory strategies

open access: yesThe FEBS Journal, EarlyView.
RNA and DNA viruses can manipulate host cell death through various mechanisms. RNA viruses (H1N1, SARS‐CoV‐2) induce acute apoptosis, necroptosis, and pyroptosis to promote rapid viral transmission and epithelial barrier damage. In contrast, DNA viruses (HSV‐1, EBV) regulate these mechanisms to sustain a lytic‐latency cycle, evade immune response and ...
Panagiotis Keramidas   +4 more
wiley   +1 more source

Exposure to angiotensin-converting enzyme inhibitors that cross the blood-brain barrier and the risk of dementia among people with HIV. [PDF]

open access: yesAIDS
Cummings TH   +7 more
europepmc   +1 more source

Surface charge alterations in urinary extracellular vesicles mirror diabetic kidney disease pathophysiology

open access: yesThe FEBS Journal, EarlyView.
This study reveals that changes in the electrical charge, that is zeta potential of large extracellular vesicles (uEVs) found in urine, can reflect disease progression from diabetes to kidney scarring (fibrosis). With further clinical development, measurement of uEVs charge could provide a simple, noninvasive way to monitor disease progression and help
Melanie Tepuš   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy